SciNeuro Pharmaceuticals
PrivateLast Round
VC Round
Dec 4, 2025
Total Funding Raised
$153M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
SciNeuro Pharmaceuticals is a biotechnology company that develops innovative drugs and therapies for the treatment of central nervous system and neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SciNeuro Pharmaceuticals Comparables
Compare SciNeuro Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neuron23 | 83% | |
| Korsana Biosciences | 82% | |
| Alector | 76% |
SciNeuro Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Dec 4, 2025 | ||||
| Series B | Dec 4, 2025 | ||||
| Series A | Dec 8, 2020 |
SciNeuro Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boyu Capital | Series A |
| Zoo Capital | Series A |
| TF Capital | Series A |
| ARCH Venture Partners | VC Round, Series B, Series A |
| ARCH Venture Partners | Series B, Series A |
| Sequoia Capital | Series A |
| The Michael J. Fox Foundation for Parkinson's Research | VC Round, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 12, 2026
Developing a new de novo amyloid beta antibody program in collaboration with Novartis.
- Jan 12, 2026
Exclusive worldwide licensing deal with Novartis Pharma AG for Alzheimer's drug.
SciNeuro Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about SciNeuro Pharmaceuticals's valuation, stock price, and market status.
Is SciNeuro a public or private company?
SciNeuro is a private company.
What is the current stock price of SciNeuro?
SciNeuro is a private company with no public stock price. No recent secondary market data is available.
How much is SciNeuro worth (valuation)?
Valuation information for SciNeuro is not publicly available.
Can I buy SciNeuro stock?
SciNeuro shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was SciNeuro's last funding round?
SciNeuro's most recent funding round was Series B on December 4, 2025.
Who are the main investors in SciNeuro?
Key investors in SciNeuro include ARCH Venture Partners, ARCH Venture Partners, Lilly Asia Ventures, Lilly Asia Ventures.
Will SciNeuro IPO soon?
No public IPO plans have been announced for SciNeuro.
How can I track SciNeuro secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor SciNeuro's secondary market activity and sign up for updates.